Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, study comparing ARIMIDEX with NOLVADEX as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 [at least 3cm], T3, N0-2, M0) or potentially operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer

Next Previous
X
Search
Trial Profile

A randomised, double-blind, study comparing ARIMIDEX with NOLVADEX as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 [at least 3cm], T3, N0-2, M0) or potentially operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Tamoxifen
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PROACT

    • Most Recent Events

    • 12 May 2009 Patient numbers amended from 451 to 452 as reported by ClinicalTrials.gov.
    • 05 Feb 2008 Status changed from in progress to completed; according to clinicaltrials.gov.
    • 29 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top